Zenas BioPharma, Inc. (ZBIO)

In the past six months, Zenas BioPharma's stock has experienced a -23.13% change, with a stock price of $20.79 as of April 8, 2026, and a market capitalization of $1.3 billion. On March 16, 2026, Zenas BioPharma reported its fourth quarter and full year 2025 financial results and provided a corporate update, including expectations to submit obexelimab marketing applications for IgG4-RD to the FDA in Q2 2026 and to the EMA in H2 2026, based on positive Phase 3 INDIGO trial results. On February 17, 2026, Purcell & Lefkowitz LLP announced a shareholder investigation of Zenas BioPharma, Inc.. On May 15, 2025, the company reported first-quarter 2025 financial results and corporate updates, including expected topline results from the Phase 3 INDIGO trial in IgG4-RD around year-end 2025, and from the Phase 2 MoonStone trial in Relapsing Multiple Sclerosis in early Q4 2025, and noted a cash runway into the fourth quarter of 2026.

The provided information does not contain details regarding demand seasonality for Zenas BioPharma, Inc.'s products and services. Demand for its products, once commercialized, would likely be driven by disease prevalence, treatment efficacy, and regulatory approvals rather than typical seasonal patterns.

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing and commercializing immunology-based therapies for autoimmune and rare diseases. Founded on November 12, 2019, and headquartered in Waltham, Massachusetts, its lead product candidate is obexelimab, a bifunctional monoclonal antibody being developed for multiple indications like IgG4-RD, RMS, and SLE. The company's pipeline includes programs such as orelabrutinib, ZB021, ZB022, ZB002, ZB004, ZB001, ZB005 and ZB014.

Zenas BioPharma, Inc. is headquartered in Waltham, Massachusetts, United States, and has a global presence with team members and partners in the United States, Europe, and Asia. Its wholly-owned subsidiaries include Zenas BioPharma (HK) Limited, Zenas BioPharma (USA) LLC, Shanghai Zenas Biotechnology Co. Limited, Zenas BioPharma Securities Corp., and Zenas BioPharma GmbH.

The provided information does not contain specific details about Zenas BioPharma, Inc.'s brand reputation in the past year. However, the announcement of a shareholder investigation in February 2026 could potentially impact reputation. The company emphasizes its commitment to scientific rigor, conducting extensive preclinical studies and clinical trials to develop effective and well-tolerated medicines.

Zenas BioPharma, Inc. is a publicly held company and was formerly VC-backed.